Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Aachen, absorb, Academy, analyze, analyzing, anatomic, antibiotic, arose, ARUP, ATM, Authorisation, Autobahn, autoleucel, AVEO, Axogen, behaviour, Biomedical, BioNJ, Biopharma, bispecific, Blackstone, Bonn, Boston, Braendle, Brent, Breyanzi, BS, BV, BX, cardiac, carve, cascade, categorized, CCR, classic, classical, CMC, contemplation, costimulatory, counterparty, Curie, cut, daily, Dainippon, deactivation, deadlock, debilitate, Denver, dialled, digit, disbursement, disbursing, Disc, displace, downside, dSHP, Edgar, effector, eighteen, embedded, encumber, encumbering, faster, fell, fifteen, FKBP, floor, foot, Forge, fourteen, Franchise, FRB, freestanding, GMP, GP, guaranty, heterodimerise, hierarchy, Hodgkin, ID, IFN, ImClone, imputed, Journal, Juno, LabCorp, LAVA, Los, LP, Lugano, lymphodepletion, MBA, Melinta, Merck, metabolic, mid, Moderna, ModernaTX, Monogram, Nanostring, necessitate, neutropenia, NYSE, obecabtagene, opted, outset, paradigm, pathology, Pfizer, pharmacodynamic, PhRMA, poised, Portola, PR, proliferative, Purdue, quoted, ready, rearm, recertification, Reef, rental, repeat, reprogram, Rice, safest, Sanofi, Schering, SDPO, seasoned, speed, stably, steering, straight, stream, Strongbridge, Stroudsburg, Sumitomo, SVP, TetCAR, TG, TGF, Theravance, thinly, tumour, tuneable, Ulm, unamortized, unencrypted, unobservable, urology, VBI, Verastem, Vertex, Village, VP, wait, Whitewood
Removed:
Backsolve, book, British, matching, OPM, reconciling, retroactively, scenario, Tabular, unlevered
Filing tables
Filing exhibits
Associated AUTL transcripts
AUTL similar filings
Filing view
External links
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-8 No. 333-226457) pertaining to the Autolus Limited 2017 Share Option Plan and Autolus Therapeutics plc 2018 Equity Incentive Plan, and
(2)Registration Statement (Form F-3 No. 333-258556) of Autolus Therapeutics plc and in the related Prospectus
of our report dated March 10, 2022, with respect to the consolidated financial statements of Autolus Therapeutics plc included in this Annual Report (Form 20-F) of Autolus Therapeutics plc for the year ended December 31, 2021.
/s/ Ernst & Young LLP
Reading, United Kingdom
March 10, 2022